Literature DB >> 8728179

Effect of different buffers on the biocompatibility of CAPD solutions.

H T Schambye1.   

Abstract

Commercially available solutions for continuous ambulatory peritoneal dialysis (CAPD) affect the viability and function of the cells in the peritoneal cavity. The low biocompatibility of the solutions may be caused by a low pH, hyperosmolality, high glucose content, and lack of potassium, glutamine, and other components essential for normal cellular functions. The nature of the buffer employed is also important for the cytotoxicity of the solutions. Lactate, the most frequently used buffer, has been shown to inhibit cellular functions important for the peritoneal defense system including phagocytosis, bacterial killing, and secretion of cytokines. It is generally believed that the cytotoxicity of lactate is caused by lowering of intracellular pH and impairment of metabolism due to changed redox potentials. However, the cytotoxicity of lactate is highly dependent upon the pH of the solutions, indicating that passive or active diffusion across the cell membrane is determining the effects of lactate. Bicarbonate has been heavily advocated as an alternative buffer because it is the most important naturally occurring buffer in plasma and it enables a pH of approximately 7.4 in the solutions. However, due to sedimentation of calcium carbonate (CaCO3) and production of toxic glucose metabolites it is difficult to prepare and store bicarbonate-based solutions. Moreover, investigations have revealed that even bicarbonate-based solutions are not optimal regarding biocompatibility, presumably due to a paradoxical intracellular acidification caused by influx of carbon dioxide (CO2). More recently, the effect of other buffers such as pyruvate and histidine have been examined. Especially pyruvate is a promising new buffer candidate.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8728179

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  9 in total

1.  Trials (and tribulations) of biocompatible peritoneal dialysis fluids.

Authors:  David W Johnson; Yeoungjee Cho; Fiona G Brown
Journal:  Perit Dial Int       Date:  2012 May-Jun       Impact factor: 1.756

2.  Biocompatibility of a new PD solution for Japan, Reguneal™, measured as in vitro proliferation of fibroblasts.

Authors:  Bart Dioos; Goedele Paternot; Rose-Marie Jenvert; Annick Duponchelle; Mark R Marshall; Migaku Nakajima; Edward Ramirez Ganoza; James A Sloand; Anders P Wieslander
Journal:  Clin Exp Nephrol       Date:  2018-06-20       Impact factor: 2.801

3.  The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial.

Authors:  David W Johnson; Fiona G Brown; Margaret Clarke; Neil Boudville; Tony J Elias; Marjorie W Y Foo; Bernard Jones; Hemant Kulkarni; Robyn Langham; Dwarakanathan Ranganathan; John Schollum; Michael G Suranyi; Seng H Tan; David Voss
Journal:  Perit Dial Int       Date:  2012 Sep-Oct       Impact factor: 1.756

4.  Association of biocompatible peritoneal dialysis solutions with peritonitis risk, treatment, and outcomes.

Authors:  Yeoungjee Cho; Sunil V Badve; Carmel M Hawley; Stephen P McDonald; Fiona G Brown; Neil Boudville; Kym M Bannister; Philip A Clayton; David W Johnson
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-15       Impact factor: 8.237

5.  Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function.

Authors:  David W Johnson; Margaret Clarke; Vanessa Wilson; Feidhlim Woods; Fiona G Brown
Journal:  BMC Nephrol       Date:  2010-09-16       Impact factor: 2.388

6.  A new peritoneal dialysis fluid for Japanese patients: a randomized non-inferiority clinical trial of safety and efficacy.

Authors:  Masaaki Nakayama; Yoshindo Kawaguchi; Takashi Akiba; Masao Kim; Hidemune Naito; Shigeko Hara; Teruhiko Maeba; Noriaki Yorioka; James A Sloand; Mark R Marshall
Journal:  Clin Exp Nephrol       Date:  2016-10-25       Impact factor: 2.801

7.  Biocompatible peritoneal dialysis fluids: clinical outcomes.

Authors:  Yeoungjee Cho; Sunil V Badve; Carmel M Hawley; Kathryn Wiggins; David W Johnson
Journal:  Int J Nephrol       Date:  2012-11-28

8.  The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial.

Authors:  David W Johnson; Fiona G Brown; Margaret Clarke; Neil Boudville; Tony J Elias; Marjorie W Y Foo; Bernard Jones; Hemant Kulkarni; Robyn Langham; Dwarakanathan Ranganathan; John Schollum; Michael G Suranyi; Seng H Tan; David Voss
Journal:  Nephrol Dial Transplant       Date:  2012-08-01       Impact factor: 5.992

9.  Biocompatible dialysis fluids for peritoneal dialysis.

Authors:  Htay Htay; David W Johnson; Kathryn J Wiggins; Sunil V Badve; Jonathan C Craig; Giovanni Fm Strippoli; Yeoungjee Cho
Journal:  Cochrane Database Syst Rev       Date:  2018-10-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.